William E Matchett
Overview
Explore the profile of William E Matchett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pape K, Dileepan T, Matchett W, Ellwood C, Stresemann S, Kabage A, et al.
JCI Insight
. 2022 Jun;
7(12).
PMID: 35730567
Immunosuppressed patients with inflammatory bowel disease (IBD) generate lower amounts of SARS-CoV-2 spike antibodies after mRNA vaccination than healthy controls. We assessed SARS-CoV-2 spike S1 receptor binding domain-specific (S1-RBD-specific) B...
2.
Ubah O, Lake E, Gunaratne G, Gallant J, Fernie M, Robertson A, et al.
Nat Commun
. 2021 Dec;
12(1):7325.
PMID: 34916516
Single-domain Variable New Antigen Receptors (VNARs) from the immune system of sharks are the smallest naturally occurring binding domains found in nature. Possessing flexible paratopes that can recognize protein motifs...
3.
Fiege J, Block K, Pierson M, Nanda H, Shepherd F, Mickelson C, et al.
Cell Host Microbe
. 2021 Nov;
29(12):1815-1827.e6.
PMID: 34731647
Laboratory mice comprise an expeditious model for preclinical vaccine testing; however, vaccine immunogenicity in these models often inadequately translates to humans. Reconstituting physiologic microbial experience to specific pathogen-free (SPF) mice...
4.
Matchett W, Joag V, Stolley J, Shepherd F, Quarnstrom C, Mickelson C, et al.
J Immunol
. 2021 Jul;
207(2):376-379.
PMID: 34193597
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine...
5.
Matchett W, Joag V, Stolley J, Shepherd F, Quarnstrom C, Mickelson C, et al.
bioRxiv
. 2021 May;
PMID: 33948591
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing antibodies target the receptor binding domain of the spike (S) protein, a focus of successful vaccine...
6.
Fiege J, Thiede J, Nanda H, Matchett W, Moore P, Montanari N, et al.
PLoS Pathog
. 2021 Jan;
17(1):e1009292.
PMID: 33507952
The human airway epithelium is the initial site of SARS-CoV-2 infection. We used flow cytometry and single cell RNA-sequencing to understand how the heterogeneity of this diverse cell population contributes...
7.
Thiede J, Gress A, Libby S, Ronayne C, Matchett W, Noren B, et al.
J Infect Dis
. 2021 Jan;
223(8):1339-1344.
PMID: 33476387
Coronavirus disease 2019 (COVID-19) outcomes are linked to host immune responses and may be affected by antiviral therapy. We investigated antibody and cytokine responses in ACTT-1 study participants enrolled at...
8.
Joag V, Wijeyesinghe S, Stolley J, Quarnstrom C, Dileepan T, Soerens A, et al.
J Immunol
. 2021 Jan;
206(5):931-935.
PMID: 33441437
The magnitude of SARS-CoV-2-specific T cell responses correlates inversely with human disease severity, suggesting T cell involvement in primary control. Whereas many COVID-19 vaccines focus on establishing humoral immunity to...
9.
Fiege J, Thiede J, Nanda H, Matchett W, Moore P, Montanari N, et al.
bioRxiv
. 2020 Oct;
PMID: 33106802
The human airway epithelium is the initial site of SARS-CoV-2 infection. We used flow cytometry and single cell RNA-sequencing to understand how the heterogeneity of this diverse cell population contributes...
10.
Gniadek T, Thiede J, Matchett W, Gress A, Pape K, Fiege J, et al.
Transfusion
. 2020 Sep;
61(1):17-23.
PMID: 32935872
Background: The transfer of passive immunity with convalescent plasma is a promising strategy for treatment and prevention of COVID-19, but donors with a history of nonsevere disease are serologically heterogenous....